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Conctuston: Low dose ol Md substl~n0ally improved LV relaxabon in as- 
soctahcn wtth stimulation of Ca' ~TPase activity in sarceptasm~c rot=culum 
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Endothelin- 1 lET-t) is elevated in CHF, althoqgh lfs kmettcs are po0dy under. 
stood in humans, We descnbe a technique ot ~l-!abelled ET.t ('~l.ET~l) 
ifl~StOn tO d~femline total ~ ET-t kinol~cs. 
&l/efhOo~.~'lesu~: 5= nora',SiS and 5 CHF patients were sttMted. Over 5 
minutes, 50 m~'ocune~ 0f ~ l .E ' r . t  wore refused. Hemodynamics #lnd blood 
samples_ wel~ Obta i~ 31 limes over 240 minutes, Afler Cla col~lmn e~lrac. 
lion, plasma was counted m a gamma counter. ET-1 plasma levels were 
measorod using an enzyme Immunoassay lechn!¢l~,l~. Ki~,~,tics Of ~I.ET.1 
clearance were modelled thmu0h standard computer modelhng ~ystems 
Basehne O~cutating ET-! levels were elevated m the CHF palients [282 
106 pg.,~! vs 097 ± 043, P ~ 0.05) There were no changes in homo- 
dynam~,s Or Ctrcutatmg ET-I levels w~th "%I-ET-1 infusmn =n e0her group 
The kinettCS 01 ET-1 clearance were best descnbecl by a three compartment 
model wlfh a prolonged terminal half life (455 ¢ 59 minutes, normals; 20689 
~. 2017'2, CHF). The steady state volume et d~stnbubon was large but atg- 
nifcantly smaller in CHF patients (34.9 ~, 99 L~g vs 23.7 ± 6.4 P - 0.05) 
The elearanoe rate at ET-t from plasma was slower m CHF patmnts (0066 
0.0088 I.Jkg~mm vs 0.036 ~: 0.012, P = 0.05) 
Cor¢tusK~ns: Th~s stuo'y desc.bes a three compartment pharmacok,not~c 
profile for ET-1. Its terminal hall life and plasma volume at d~stnbuhoe are 
sign~ficantiy lan3er than ~ev~ous reports. The pharmacekinet~c profile of CHF 
pahents ~s altered and may explain ~ts elevatnd ctrCulating levels. 
~ l r h e  Neuronal  NorelPlnephrine Transpor ter  in 
IE=perimental Heart Fai lure A f te r  Supracoronary  
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Background: Cardiac net secretion el norepmepnnne (NE) =s increased m 
congesbve head failure. To further elumdate the role of the neuronal nore- 
pmephnne transporter (NET, uptake~ )expenments were pefforme~ m rats 
w~th supracoronary aod=c banchng. 
Methods and ResultS: Compared to sham operated control rats. rats wtth 
aortic banding were characterized by myocardial hypertrophy (heart weight 
1 77 ± 0.08 vs. 122 ~ 0.02 g). pulmonary congest=on (7.24 .- 0 38 vs 409 : 
0.16 g). and increased plasma NE (4 4 : 0.8 vs. 3.0 = 06 nmol;0 In ~solarecl 
pedused nearts funobonal ,mpa=rment el NET was md~cated by It) the uptake 
of [3H]-NE being reduced (20 ± 1 vs. 30 z 2%) and (11) pharmacelog=cal 
blockade o1 NET wtlh aesipram~ne (DMI. 300 nmot~tl leading to a d~rmntshed 
increase in endogenous NE release evoked by electncal field stlmul0hon (4 
HZ. 1 mini ($2/Sl 1.2 ± 0.2 vs. 1 7 ~ 01: St: control: St; alter DMI} in 
:: 6, p < 0.05 each). RT-PCR was used to study NET g¢~e expression 
In situ hybndlzatton v~th the DIGJabeled PCR product revealed a dense 
hybndizaticn in the penkarya cf tyrosme hydroxylase pos=tr~e cell bodies 
w0hin the left stellate ganghon but neither in efferent car~ac nerves nor the 
head. NET mRNA concentratrons of the left stellate ganglion were quantified 
by competihve RT-PCR. as was 18S rRNA to control tar intact RNA. However. 
there was no significant difference between aodic banded and sham operated 
rats (1.65 ± 0.11 vs. 1.81 ~ 0.07 NET mRNA]18S rRNA ~ 10 ~, n = 6) 
Concluston: Cardiac NE uptake by the NET is imps=red in aortic banded 
rats with head failure despde unaltered NET gene express=on 
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Without Altering the Hypertrophic Response 
During Congest ive  Heart Fa i lure in Rats 
E. Oie ~ , R, Bjomerhelm ~, H.K. Grogaard ~ . O,A. Smiseth ~. H. Attramadal ~ .
~ MSD - CVRC, Nonyay, ~ Med. Dept. B. The National Hospital University at 
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Background: The role played by endothelin-1 (ET-1) in the progression ot 
congestive heart failure (CHF) remains unknown. We investigated the effects 
of ET receptor blockade on cardiac dimensions and dynamics, and on gone 
expression markers of hypertrophy during CHF 
Methods: Alter ligation of the left coronary artery, rats were randomized 
to oral treatment with a non-selective ET receptor antagonist (Bosentan, 100 
mg/kg/day, n = 11) or saline (n = 13) for 15 days starting 24 hours after 
the tnducbon ot mycx:ardtal *ntarc1~on T0n she ,-Operated fats rece~., ' ,,o 
treatment 
Results Right venlncular wl/t:X:K~ wl tetras were incroaseo Dy 65% =~ 
both the CHF groups (p ~ 005) E~.hoca~mgrapny feveatecl an ,ncteas~ ~n 
taft ventncut~f end-O~a~tohc d~mens~orr~ (LV EDD) tram 57 • 0 1 in ~ s~'n  
group to 8,7 • 0.2 mm In the CHF-sahne group, wh*l~ tr~.'ffmnal ~
(FS) was decreased from 3~ ~ 2 to 12 z 1% (p ,: 0.05) Inteeventmn w~h 
bosentan Caused 35% red~tt0n in LV ddatatmn (LVEDD 7.6 ~ 03 ram) 
an~ 49%, increase ,n FS (to 18 z 1%) compared to vel'~cte (p ~ 005) 
Bosentan also roducect LV enc~a~ttohc PreSsgra fro~ 23 z i to 20 • 2 
mmHg and LV systole pressure from 107 ~ 3 Io 99 ~ 2 mmHQ (p ~ 0.051 
Express~on o! prepreET.1. ANP, BNP, p.MHC ar~ fikeletal ~.actin mRNAs 
were all marke~y a~d ~ignd'~csnthl mCre~od In nenq,~chem~c myoca~c~-rn ,~-~ 
CHF No drfferer~es were obsewed between the CHF gre~.  
Conclusion Intervention w=lh Bosentan dramatically improves LV pres~ 
-,ure-volume relationships and cardiac dynamics wnhout altenng the hype~, 
trophie response dunng CHF in rats 
~ ~3~ w.at le the sour~= of ,ncm~ Mwc=.d~,l ~.mo. 
Necrosis Factor-alpha In Heart Fai lure? 
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Background Tumor necrosis factor-alpha (TNF-a) Is a pleolrep=c premftam- 
matory cytokme and plasma TNF-a level appears to cater prognosis m pa- 
tlents wnb heart fadum (CHF) However, there =s debate regar~ng the soume 
at the increased TNF-a. Some investigators argue Ihet TNF-a is produced 
by =mmune activatmn at end stage CHF. We therefore studmd TNF.a ~n a 
clog model at pacmg-~nduced CHF in which there ~s IJMle tissue tnMammah~ 
re~panse. 
Mettm~s. Six dogs were nght ventncular-paced at 250 beats~rmn mr 3 
weeks to severe CHF Senal plasma levels (mean ~ SE) of TNF-a (by 
ELISA, pcjJml} and noropmephnne (NE. by HPLC, pg/ml) are shown 
• p 0 05 versus t~aselme 
Baseline Week 1 Week 2 Week 3 
TNF-a B : 4 79 ± 27" 89 z 25' 247 ~ 98" 
NE 23? t 34 391 ~ 62 445 t 74" 644 ~ ~64" 
Results: EvoMng CHF =.~ accompanied by a progresstve increase cn 
plasma TNF-a and NE Immunohistochemical studies of the LV of the paced 
ct~gs revealed intense staining for TNF-a m the myocytes, endothehal ana 
smooth muscle layers, but not m the tibreblasts. These change.~ were not 
observed in conlrel normal d~ Staining el the spleens from the paced 
dogs were s~mffar to lhe controls 
Conclusion: Increased plasma and myocardial TNF-a m a model of CHF 
with ht~le immune pathegenes=s uggests a pnmary product=on of TNF-a ~n 
the heart without a reclu~rement of immune activation. 
~ C a  ~* From Reticulum Is Release Sarcoplasmic 
Slowed Down In Heart  Failure 
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Background." In heart tadure, little informatmn is available as to the Ca ~" 
release function of SR which plays a maior role on cardiac contractility. 
Method: The SR vesicles were isolated from dog LV muscles (normal 
[N]. n = 7: pacing induced heart fadure [HF], n = 6). The lime course of 
SR Ca 2" release was car :muously monitored by a stopped-flow apparatus 
using arsen3zol[I as Ca;" indicator, and [3H]ryanoclino (Ry) binding assay 
was done using flltratmn method. 
Resu/t: As compared ~-,tth N. LV end-diastolic pressure was elevaled by 
380 • 91% (p . 001). The peak + dP/dt was decreased by 24 = 13% 
(p = 0.01) wh~le hme co, natant at LV pressure d~,.,ay dunng isovolum~c 
relaxation was increased by 19 : 8% (p - 0.01), indicating HF The amount 
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